Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301

Next Previous
Trial Profile

Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Cemiplimab (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TOP 2301

Most Recent Events

  • 10 Mar 2025 Planned End Date changed from 30 Aug 2028 to 30 Oct 2029.
  • 10 Mar 2025 Planned primary completion date changed from 30 Aug 2026 to 30 Oct 2027.
  • 10 Mar 2025 Planned initiation date changed from 15 Dec 2024 to 3 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top